Key facts
- Hyku Biosciences’s last known valuation is $85.0M (Nov 2024).
- It has raised $70.6M across 2 recorded rounds; the latest was Seed Round ($64.0M) in Nov 2024.
- Notable investors include RA Capital Management, KB Investment, Novartis Venture Fund, Chugai Venture Fund, Droia Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Hyku Biosciences
Funding rounds
2 roundsAbout Hyku Biosciences
Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. The company identifies compounds that covalently bind non-cysteine amino acids to facilitate the development of novel therapies that can address current challenges associated with many disease targets, including selectivity, druggability, and resistance, enabling patients to improve their lives by pushing the scientific boundaries of covalent medicines.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2021
- Employees
- 16
- Website
- hykubiosciences.com/
- Ownership
- Privately Held (backing)
Hyku Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hyku Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hyku Biosciences in its N-PORT filings yet. We sweep new filings monthly.